CD38+ B cells affect immunotherapy for allergic rhinitis

Gui-Xiang Tian,Ke-Ping Peng,Ming-Hui Liu,Dao-Fa Tian,Hai-Qing Xie,Li-Wen Wang,Yu-Yang Guo,Shan Zhou,Li-Hua Mo,Ping-Chang Yang
DOI: https://doi.org/10.1016/j.jaci.2022.01.012
IF: 14.29
2022-01-01
Journal of Allergy and Clinical Immunology
Abstract:BackgroundAllergen specific immunotherapy (AIT) is the mainstay in the treatment of allergic diseases. Yet the therapeutic effects of AIT need to be improved. CD38+ B cells are an immune cell fraction involving in the pathogenesis of allergic diseases as well as in the immune regulation.backgroundObjectivesTo elucidate the role of antigen specific CD38+ B cells in AIT.MethodsAn analysis was carried out on AIT results of 48 patients with perennial allergic rhinitis (AR), among which peripheral blood immune cells were analyzed by flow cytometry; serum cytokine levels were determined by ELISA. An AR murine model was developed to test the role of CD38+ B cells in AIT.ResultsA fraction of antigen-specific CD38+ B cell was detected in AR patients. CD38+ B cell frequency was negatively correlated with the therapeutic effects of AIT. A negative correlation was detected between the CD38+ B cell frequency and regulatory T cell frequency in AR patients treated with AIT. Exposure to specific antigens induced CD38+ B cells to produce IL-6, that converted Tregs to Th17 cells. Co-administration of anti-CD38 antibody significantly promoted the therapeutic effects of AIT.resultsConclusionsAntigen-specific CD38+ B cells compromise the AIT effects by producing IL-6 to convert regulatory T cells to Th17 cells. Inhibition of CD38+ B cells promotes the effects of AIT.conclusion
immunology,allergy
What problem does this paper attempt to address?